Our study findings support the view that both well-established IPF biomarkers, including KL-6, SP-D, and MMP-7, and more recently introduced ones, like CA19-9, have the potential to support clinical practice in IPF. This evidence concerns the gene SFTPD and idiopathic pulmonary fibrosis.